Sector: Technology | Industry: IT Services & Consulting |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 729 Washington Ave. N, Suite 600 MINNEAPOLIS MN 55401 |
Tel: | 1-949-5743860 |
Website: | delwinds.com |
IR: | See website |
Key People | ||
Tyler Danielson Interim Chief Executive Officer, Chief Technology Officer | Robert Potashnick Chief Financial Officer | Michael Will General Counsel | Brian Chen Chief Science Officer |
Business Overview |
FOXO Technologies Inc. is a biotechnology company. The Company is focused on commercializing longevity science through products and services that serve the life insurance industry. Its epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging. The Company operates through two segments: FOXO Labs and FOXO Life. FOXO Labs is commercializing epigenetic biomarker technology to be used for mortality underwriting and risk classification in the global life insurance industry. Its biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. FOXO Life is redefining the relationship between consumers and insurers by combining life insurance with healthy longevity. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products. |
Financial Overview |
For the three months ended 31 March 2023, Foxo Technologies Inc revenues totaled $13K. Net loss totaled to $7.6M. |